ILIAS Biologics, Inc. is a biotechnology company specializing in the development of engineered exosomes, which are tiny vesicles that can deliver therapeutic proteins to intracellular pathways that are otherwise difficult to target. The company operates in the biopharmaceutical market and primarily serves clients in the healthcare and medical research sectors. ILIAS Biologics employs a proprietary platform technology to load large therapeutic payloads inside exosomes, aiming to treat life-threatening and hard-to-treat diseases such as inflammatory bowel disease (IBD) and acute kidney injury (AKI). The company generates revenue through research and development contracts, grants, and strategic partnerships with other biotech firms and research institutions. By leveraging open innovation, ILIAS Biologics is expanding its global network of research and business alliances to maximize its potential in developing novel exosome-based therapies.

Keywords: engineered exosomes, therapeutic proteins, intracellular pathways, biopharmaceutical, healthcare, medical research, proprietary technology, IBD treatment, AKI treatment, global alliances.